ApoB vs LDL. Why the standard of care moved.

For four decades, "what is your LDL?" was the right question. The number was inscribed on every annual physical, used to score risk, and used to start statins. In 2026, the question has changed. The new question is "what is your ApoB?" — and most members of premium-wellness practices still have not had it tested.

The answer to why this moved is not new science. It is forty years of accumulated evidence that finally crossed the threshold where the consensus guidelines could no longer hold the older marker in place. The American Heart Association updated its preventive-cardiology guidance in 2024. The European Society of Cardiology and European Atherosclerosis Society did the same. Both bodies now position ApoB as the primary atherogenic lipid marker.^1,2

This is the explanation, in the order it actually matters.

What ApoB measures, and why it differs from LDL-C

Atherosclerosis — the thickening of arterial walls that produces heart attacks and strokes — is caused by lipoprotein particles depositing cholesterol into the arterial intima. The particles in question are LDL, VLDL, IDL, chylomicron remnants, and Lp(a). Each one of these particles carries exactly one ApoB protein on its surface.

That single fact is the entire argument. ApoB is a count of every atherogenic particle in the bloodstream. Measure ApoB, and you have measured the cause.

LDL-C, by contrast, is a measurement of the cholesterol cargo inside the LDL fraction of those particles. It is not even measured directly in most lab workflows — the standard panel calculates LDL-C from total cholesterol, HDL-C, and triglycerides using the Friedewald equation. The calculation breaks down in members with high triglycerides, low LDL, or atypical particle composition.³

You can have a perfectly "normal" LDL-C with a dangerous ApoB. The cargo per particle has shifted; the particle count has not.

The "discordance" problem — and who is hiding inside it

In about 20% of adults, LDL-C and ApoB disagree by enough to change clinical management.⁴ Cardiology literature calls this discordance. The members most likely to land in the discordant group are exactly the ones a premium-wellness practice serves:

• Members with metabolic syndrome or insulin resistance — small, dense LDL particles dominate; ApoB rises while LDL-C looks reassuring.
• Members on aggressive low-carb or ketogenic diets — triglycerides drop, LDL-C calculation distorts.
• Members with elevated Lp(a) — LDL-C cannot see it; ApoB includes it.
• Members already taking a statin — LDL-C may look "controlled" while ApoB shows residual particle burden.

In every one of these cases, ApoB tells the truer story. Discordance studies consistently show that when LDL-C and ApoB disagree, cardiovascular event rates track ApoB, not LDL-C.^4,5 The Mendelian-randomization work of Ference and colleagues established this causally: lifelong variation in ApoB has a dose-response relationship with coronary disease, and the effect of LDL-C is fully explained by its correlation with ApoB.⁵

If LDL-C and ApoB disagree, the cardiovascular events track ApoB. The implication is not subtle.

The 2024 guideline shift

The two most authoritative preventive-cardiology guidelines in the world updated their position in 2024.

The American Heart Association's preventive-cardiology guidance moved ApoB into the primary-marker position, recommending its use in primary prevention for any adult with metabolic risk factors and as the on-treatment monitoring marker for anyone on lipid-lowering therapy.¹ The European Society of Cardiology and European Atherosclerosis Society dyslipidaemia guidelines positioned ApoB as the preferred risk marker over non-HDL-C in members with high triglycerides, diabetes, obesity, or very low LDL-C levels — which covers most of the people who walk into a premium practice asking about cardiovascular optimization.²

This is not a fringe position or a "functional medicine" reframe. It is the major-society consensus, in writing, in the documents that primary-care physicians are supposed to follow. The lag is just that most clinical labs still default to LDL-C on the standard panel, and most physicians never order ApoB because it requires a separate add-on.

What ApoB costs, and why it is missing from your last physical

The most striking thing about ApoB is how cheap it is. The cash price at Quest or LabCorp is roughly $25.⁶ Most insurance plans cover it with an appropriate ICD-10 code — metabolic syndrome, hyperlipidemia, family history, atherosclerotic disease — meaning the member's actual cost is often zero.

The reason ApoB is missing from most physicals is institutional inertia, not cost or controversy. The standard lipid panel auto-generated by an EMR's order set runs total cholesterol, LDL-C (calculated), HDL-C, and triglycerides. ApoB has to be added as a separate order. If the ordering physician's training predates the guideline shift, ApoB doesn't get added.

At Wellness Elite Fitness, ApoB is part of the standing executive panel. So is Lp(a) — the heritable, once-in-a-lifetime cardiovascular marker that statins do not lower and that about one in five adults carries elevated. Together, ApoB and Lp(a) are the 2026 cardiovascular foundation. Both are on our published panel.

Reading your ApoB

The reference range from a standard laboratory will look something like "< 130 mg/dL = normal." That is the disease-screening threshold. For preventive cardiology and longevity-medicine purposes, the optimal range sits considerably lower:

ApoB range	What it represents
< 130 mg/dL	Standard laboratory "normal"
< 80 mg/dL	Optimal for cardiovascular prevention (general population)
< 60 mg/dL	Aggressive prevention target for members with elevated Lp(a), strong family history, or established atherosclerosis

The optimal target is informed by the same Mendelian-randomization evidence that drove the guideline change. The lower ApoB runs over a lifetime, the less atherosclerotic plaque accumulates. There is no plausible "too low" threshold in the cardiovascular literature — the relationship is linear and continuous, all the way down.⁵

Lp(a) — the marker hiding behind your father's heart attack

While we are restructuring the cardiovascular panel, the second marker that warrants attention is Lp(a) (pronounced "L-P-little-a"). Lp(a) is an LDL particle with an additional protein called apolipoprotein(a) attached. It is genetically determined — your Lp(a) is largely the same at age 70 as it was at age 30. Diet, exercise, and statins do not meaningfully lower it.⁷

About 20% of adults carry elevated Lp(a). Elevated Lp(a) carries independent risk for coronary disease, ischemic stroke, and aortic stenosis — in some studies, doubling cardiovascular event risk independent of LDL-C and other lipids.⁸

The clinical importance of knowing your Lp(a) is twofold. First, it explains the "premature heart disease in the family with no clear reason" pattern that runs in many members' family histories. Second, it shifts the prevention strategy — members with elevated Lp(a) should target a lower ApoB and a lower LDL-C than the general population.

Lp(a) is the rare lab test that is genuinely once per lifetime. Test it once, record the number, and apply the information to every prevention decision going forward.

The bigger picture

What ApoB and Lp(a) represent is not a niche or boutique reframing of cardiovascular medicine. They represent the actual state of the field, several years after the guideline bodies moved and several years before the average physical caught up. A premium-wellness practice that does not test them is operating at the standard of 2010, not the standard of 2026.

At WEF, ApoB and Lp(a) are part of the standing executive panel. So are 47 other markers chosen for their evidence base, their actionability, and their relevance to the long arc — not just to next year's physical.